Meridian Bioscience Added to Mergent's Dividend Achievers Index(TM)
CINCINNATI--(BUSINESS WIRE)--May 3, 2006--Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ:VIVO) today announced that it has been added to Mergent's Dividend Achievers Index(TM) for 2006. This index is made up of just 3% of U.S. publicly traded companies with the most consistent records of annual dividend increases.
Quoting from Mergent's correspondence, "This designation means that you (Meridian Bioscience, Inc.) are part of an elite class of companies that have successfully delivered dividend increases to shareholders for 10 or more consecutive years. Dividend Achievers are strong companies with the potential to outperform broad based indices over the long term. In fact, over the past 10 years through 2005, Mergent's Dividend Achievers Index has outperformed the S&P 500 Index by an annualized rate of 1.8% per year."
William J. Motto, Chairman and Chief Executive Officer, stated, "We are very pleased to be included in the Mergent's Dividend Achievers Index(TM) for the third year in a row. Our long-standing cash dividend policy has served shareholders well with fourteen increases during the past sixteen years. Our current indicated annual cash dividend rate is $0.46 per share. With our strong cash flow from operations, we are able to internally fund the company's growth and concurrently payout between 75% and 85% of our net earnings in cash dividends to shareholders."
Meridian is a fully integrated life science company that manufactures, markets and distributes a broad range of innovative diagnostic test kits, purified reagents and related products and offers biopharmaceutical enabling technologies. Utilizing a variety of methods, these products provide accuracy, simplicity and speed in the early diagnosis and treatment of common medical conditions, such as gastrointestinal, viral, and respiratory infections. Meridian diagnostic products are used outside of the human body and require little or no special equipment. The Company's products are designed to enhance patient well-being while reducing the total outcome costs of healthcare. Meridian has strong market positions in the areas of gastrointestinal and upper respiratory infections, serology, parasitology and fungal disease diagnosis. In addition, Meridian is a supplier of rare reagents and specialty biologicals along with proteins and other biologicals used by biopharmaceutical companies engaged in research for new drugs and vaccines. The Company markets its products to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices and diagnostics manufacturers in more than 60 countries around the world. The Company's shares are traded through Nasdaq's National Market, symbol VIVO. Meridian's website address is www.meridianbioscience.com.
CONTACT: Meridian Bioscience, Inc.
John A. Kraeutler, 513-271-3700
SOURCE: Meridian Bioscience, Inc.